R-CHOP
Checked 2026-09-09
Diffuse large B-cell lymphoma, first line (6 cycles; 3-4 with radiotherapy for limited stage)
One cycle
every 21 days × 6 · about 18 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Rituximab Monoclonal antibody (anti-CD20, chimeric) | 375 mg/m² | IV | D1 | |
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug) | 750 mg/m² | IV | D1 | |
Doxorubicin Cytotoxic chemotherapy (anthracycline) | 50 mg/m² | IV | D1 | |
Vincristine Vinca alkaloid (microtubule inhibitor) | 1.4 mg/m² (maximum 2 mg) | IV | D1 | |
Prednisone | 100 mg once daily | Oral | D1-5 |
Cycles
6
21-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Consider (10-20% FN risk)
Notes
- G-CSF is recommended for patients over 65 or with comorbidity (FN risk 10-20%).
- Hepatitis B serology before rituximab; check LVEF before doxorubicin.
Used in
Trials
Source
Coiffier (GELA LNH-98.5), NEJM 2002
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Pola-R-CHP
Untreated DLBCL, IPI 2-5
every 21 days × 6
R-ICE
Relapsed or refractory DLBCL, salvage before autologous transplant (late relapse) or bridging
every 14 days × 2-3
Bendamustine + rituximab (BR)
Indolent lymphoma and mantle cell lymphoma first line; fit CLL without del(17p) where targeted agents are unavailable
every 28 days × 6
Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T
Relapsed or refractory large B-cell lymphoma (second line if refractory or relapse within 12 months), B-ALL, follicular and mantle cell lymphoma
every 6 days